Saturday 17 October 2026 Export IBRX’s income statement to Excel — free account

ImmunityBio, Inc.

ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024. In the quarter to June 2026, revenue grew 93.9%, EPS fell 120.0%, free cash flow grew 13.4% and total debt rose 57.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

9.18 0.82 −8.20%

Follow IBRX

Alert me

Market cap: $10.6B
P/E: 0.0×
Fwd P/E: −8.1×
Dividend yield: —
F-score: 4/9
Altman Z: −10.16
Beneish M: 4.57
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 9.51

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	2	3	—	—	—	3	2	—	—	2

Insider Ownership 61.81%

Capital & Financial Ratios $m

Market Cap 10,600.00

Revenue 165.79

Net Income (992.42)

Free Cash Flow (288.07)

Net Debt 416.98

Current Ratio 5.72

Debt/Equity (0.74)

P/E ratio 0.00

Fwd P/E (8.14)

P/S ratio 58.14

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (152.63%)

Next Y EPS Growth 88.28%

Next Y revenue growth 100.02%

Next 5Y EPS Growth 57.53%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 10.14%

10-year low 10-year high

EV/Sales against its own 10 years 9.92%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	266	150	243	357
Receivables	—	2	43	53
Inventory	—	8	1	2
Other	2	0	0	0
	294	185	315	439

	2023	2024	2025	Q'26
Payables	9	7	7	12
ST’ Debt	—	—	—	—
Other	—	—	—	—
	58	55	62	77

Compound Annual Growth %

	10y	5y	3y
Sales	85.41%	184.76%	678.62%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	44	51	—	—	—
’25	17	26	32	38	113
’24	0	1	6	8	15
’23	0	0	0	0	1
’22	0	0	0	0	0
’21	0	0	0	0	1
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(75)	(66)	—	—	—
’25	(86)	(80)	(69)	(70)	(305)
’24	(107)	(100)	(99)	(85)	(391)
’23	(84)	(80)	(87)	(115)	(367)
’22	(75)	(91)	(81)	(91)	(338)
’21	(60)	(70)	(73)	(72)	(274)
’20	(31)	(46)	(37)	(58)	(172)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(77)	(70)	—	—	—
’25	(87)	(81)	(70)	(71)	(309)
’24	(108)	(101)	(102)	(87)	(398)
’23	(93)	(88)	(93)	(123)	(397)
’22	(124)	(107)	(97)	(110)	(437)
’21	(68)	(78)	(60)	(82)	(287)
’20	(31)	(46)	(39)	(57)	(173)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.62)	(0.22)	—	—	—
’25	(0.15)	(0.10)	(0.07)	(0.06)	(0.38)
’24	(0.20)	(0.20)	(0.14)	(0.09)	(0.62)
’23	(0.27)	(0.32)	(0.19)	(0.38)	(1.15)
’22	(0.26)	(0.24)	(0.28)	(0.27)	(1.04)
’21	(0.21)	(0.23)	(0.23)	(0.23)	(0.90)
’20	(0.10)	(0.14)	(0.17)	(0.18)	(0.59)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.43	2.71	0.93	0.95	2.52	5.11	2.60	1.21	2.50	1.83	Analyst estimates 2026–2028 Powerpack
	High	16.90	8.45	5.47	4.89	19.37	45.42	7.85	6.93	10.53	4.27
People
People	Employees	82	139	161	148	171	587	725	628	680	691
	Revenue/emp, $m	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.02	0.16
Income, $m
Income, $m	Revenue	0	0	0	2	1	1	0	1	15	113
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	99.34
	EBT	(121)	(97)	(97)	(160)	(226)	(350)	(417)	(584)	(414)	(352)
	EBT margin, %	(275,865.91)	(215,368.89)	(205,806.38)	(7,278.07)	(37,360.83)	(37,456.00)	(173,869.17)	(93,873.31)	(2,805.32)	(310.37)
	Net income	(121)	(96)	(96)	(160)	(224)	(350)	(417)	(584)	(414)	(351)
	Depreciation	6	7	10	14	14	15	36	62	40	16
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.02	0.12
	Earnings	(1.47)	(1.20)	(1.22)	(0.44)	(0.59)	(0.90)	(1.04)	(1.15)	(0.59)	(0.38)
	Cash flow	(0.47)	(0.61)	(0.80)	(0.42)	(0.46)	(0.70)	(0.84)	(0.72)	(0.56)	(0.33)
	Capex	(0.08)	(0.43)	(0.16)	(0.01)	0.00	(0.03)	(0.25)	(0.06)	(0.01)	0.00
	Free cash flow	(0.55)	(1.04)	(0.96)	(0.43)	(0.46)	(0.74)	(1.09)	(0.78)	(0.57)	(0.34)
	Book value	3.58	2.72	1.85	0.33	(0.31)	(0.63)	(1.12)	(1.15)	(0.70)	(0.54)
	Shares, m	82	81	79	366	377	389	400	509	697	920
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	11,011.27	7,843.51	1,953.05	630.50	8,307.96	2,533.77	7,948.01	4,284.97	121.07	16.08
	P/B	1.65	1.61	0.63	11.50	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	6,536.36	5,365.04	818.49	613.79	8,581.04	2,845.85	10,306.30	5,727.04	174.91	22.40
	EV/FCF	(6.37)	(2.89)	(0.51)	(8.65)	(29.94)	(9.23)	(5.66)	(8.97)	(6.48)	(8.22)
Cash, $m
Cash, $m	Operating cash flow	(39)	(49)	(63)	(152)	(172)	(274)	(338)	(367)	(391)	(305)
	Capex	(7)	(35)	(13)	(4)	(2)	(13)	(99)	(31)	(7)	(4)
	Free cash flow	(45)	(84)	(76)	(156)	(173)	(287)	(437)	(397)	(398)	(309)
Balance, $m
Balance, $m	Working capital	193	112	62	44	44	(35)	(360)	236	130	253
	Total debt	3	2	7	15	261	609	673	682	462	477
	Net debt	(196)	(126)	(67)	(37)	165	291	566	415	312	234
	Shareholders’ equity	293	219	146	121	(118)	(244)	(450)	(586)	(488)	(500)
Returns, %
Returns, %	ROA	(35.31)	(33.96)	(44.51)	(97.07)	(121.73)	(100.48)	(100.22)	(134.56)	(93.21)	(79.43)
	ROIC	(80.17)	(66.58)	(78.07)	(116.43)	(295.46)	(433.97)	(189.00)	0.00	0.00	0.00
	ROE	(37.21)	(37.65)	(52.75)	(118.32)	(20,269.62)	191.38	120.09	112.61	77.01	71.15

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
MDGL Madrigal Pharmaceuticals, Inc.	$10.6B	— (loss-making)	— (loss-making)	+71.17% (above 0%: growing)	n/m	+140.54% (above 0%: growing)	89.02%	(15.46%)	Compare
IBRX ImmunityBio, Inc.	$10.6B	— (loss-making)	— (loss-making)	+93.91% (above 0%: growing)	n/m	+13.38% (above 0%: growing)	99.42%	(120.41%)
PCVX Vaxcyte, Inc.	$10.3B	— (loss-making)	—	—	n/m	−92.55% (below 0%: shrinking)	0.00%	0.00%	Compare
KRYS Krystal Biotech, Inc.	$9.8B	38.3×	38.6×	+24.14% (above 0%: growing)	+39.10% (above 0%: growing)	+40.14% (above 0%: growing)	94.60%	49.00%	Compare
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)	Compare
Median of peers	$10.7B	103×	38.1×	+24.14%	+21.21%	−13.55%	84.27%	5.61%

All 614 Biotechnology stocks →

ImmunityBio, Inc. (IBRX) key facts

Strength: ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
ImmunityBio, Inc. (IBRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IBRX traded at $9.18, a market capitalization of $10.6 billion.
Return on equity was 71.2% and debt-to-equity -0.74.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −10.16 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.